China drugmaker begins trial production of AstraZeneca COVID-19 vaccine
SHENZHEN -- A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
- Erhai Lake locals prosper from improved environment
- Doctor injects child with improperly stored drug at Chongqing hospital
- Xi's special envoy attends forum dedicated to Intl Year of Peace and Trust in Turkmenistan
- Memorial ceremony remembers victims of Nanjing Massacre
- Louvre's largest showcase in China goes on display at Museum of Art Pudong in Shanghai
- Indonesian foundation to fund students, school administrators to exchange and study in Tianjin
